Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary: The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid \[ICS\]/ Long-acting Muscarinic Receptor Antagonists \[LAMA\])/ Long Acting Beta-Agonist \[LABA\] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD


Options:
A: Arm Label: fluticasone furoate/umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI) | Arm Label: umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Intervention Type: DRUG; Name: fluticasone furoate (FF); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: vilanterol (VI); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol, umeclidinium bromide/vilanterol | Intervention Type: DRUG; Name: umeclidinium bromide (UMEC); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, umeclidinium bromide/vilanterol
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg, Drug: Placebo to salmeterol | Arm Label: Salmeterol 50 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 µg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Salmeterol 50 µg; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to salmeterol; Assigned to Arm(s): Indacaterol 150 µg
C: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)

Answer: A